My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Emtricitabine (BW1592)
    Emtricitabine (BW1592)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1813
    CAS #: 143491-57-0 Purity ≥98%

    Description: Emtricitabine (BW1592; FTC; Coviracil; Emtriva; Racivir) is a potent nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 µM and has been used for the treatment of both human immunodeficiency virus (HIV) and hepatitis B virus. Emtricitabine is structurally similar to Lamivudine. It is effective at targeting HIV and HBV viruses since these viruses replicate in a reverse transcriptase manner. Studies indicate that the structure of Emtricitabine, specifically the unnatural β-L structural configuration produce greater antiviral effects in vitro on HIV and HBV than other antiviral agents. nucleoside reverse transcriptase inhibitor 

    References: Antivir Ther. 2007;12(7):1075-85; Antivir Ther. 2006;11(3):377-84.

    Related CAS#:152128-77-3 (Emtricitabine S-oxide); 160707-69-7 [Apricitabine, (-)-BCH-10652; (-)-dOTC; AVX-754; BCH-10618; SPD-754]; 1011529-10-4 (Azvudine; FNC; RO-0622; RO 0622; RO062); 634907-30-5 (OBP 601; BMS-986001; BMS 986001; BMS986001; festinavir; 4′-Ed4T; Censavudine); 147221-93-0 (Delavirdine mesylate) 136817-59-9 (Delavirdine free base); 181785-84-2 (Elvucitabine)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)247.25
    FormulaC8H10FN3O3S 
    CAS No.143491-57-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 49 mg/mL (198.2 mM)
    Water: 49 mg/mL (198.2 mM)
    Ethanol: 9 mg/mL (36.4 mM)
    Other infoChemical Name: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
    InChi Key: XQSPYNMVSIKCOC-NTSWFWBYSA-N
    InChi Code: InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
    SMILES Code: C1[[email protected]](O[[email protected]](S1)CO)N2C=C(C(=NC2=O)N)F
    SynonymsBW-1592; BW1592; BW 1592; trade names: Coviracil; Emtriva; Racivir; (-)-FTC; W-201247; W-201248; E1007; 24229-EP2298783A1; 24229-EP2314590A1; AB01275429-01; 3B2-0188


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells. Emtricitabine plus tenofovir slightly reduced cell proliferation without affecting mitochondrial parameters. Emtricitabine efficiently converts to their active metabolites in PBMCs and CEM cells. Emtricitabine combined with Tenofovir displays additive to synergistic activity against HIV replication in PBMCs and results in strongly synergistic anti-HIV activity in MT-2 cells against both wild-type and mutant virus. Emtricitabine demonstrates antiviral activity against laboratory adapted strains of HIV-1 and HIV-2 in various cell system. Emtricitabine also exhibits antiviral activity in cell culture against feline and simian immuno-deficiency viruses (SIVs). Emtricitabine consistently exhibits up to 10-fold greater activity than lamivudine against all viruses tested in all T-cell lines. Emtricitabine generally demonstrates greater potency in vitro in human PBMCs than in MT-4 lines. Emtricitabine also exhibits anti-HBV activity in vitro (EC50, 0.01–0.04 µM) that is comparable to the anti-HBV activity of 3TC. Emtricitabine is approximately fourfold more active than 3TC in assays in the transformed T-cell line MT-4 infected with HIV-(1IIIB), whereas Zidovudine is more active than Emtricitabine. Emtricitabine, Lamivudine and Zidovudine are equally active against a panel of eight primary HIV-1 isolates from antiretroviral-naive subjects in PBMCs.


    Cell Assay: Emtricitabine, an antiretroviral agent is used to evaluate degradation pathways under different stress conditions in order to identify degradation products as prescribed by ICH guidelines. Emtricitabine degrades over 51%, 13% and 53% during acid, base and oxidative degradation respectively followed by formation of three major degradation products (Degradant-I to Degradant-III).

    In VivoReproductive and developmental toxicology studies are conducted with emtricitabine. Oral doses up to 1000 mg/kg/day provided daily area under the curve (AUC0→24) exposure to pregnant animals approximately 60- (mice) to 120-fold (rabbits) higher than that in humans at the recommended dose of 200 mg given once per day. In a mouse fertility study, emtricitabine had no effect on fertility, sperm count, or early embryonic development. There is no increased incidence of malformations in mouse and rabbit embryofetal toxicology studies. The development and fertility of F1 progeny are unaffected by emtricitabine in a mouse pre- and post-natal study. These data demonstrate a favorable pre-clinical reproductive safety profile for emtricitabine
    Animal modelMouse
    Formulation & DosageOral 
    ReferencesAntivir Ther. 2007;12(7):1075-85; Antivir Ther. 2006;11(3):377-84.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?